2020
PLEASE note: An article with the comment (NOT OA) means that it is not available with Open Access. Please contact susanne.noll@uct.ac.za should you wish to read the full article.
First results of phase 3 trial of RTS,S/AS01 malaria vaccine in African children. (2011). New England Journal of Medicine, 365(20), 1863-1875. (NOT OA)
2. Efficacy and safety of the RTS,S/AS01 malaria vaccine during 18 months after vaccination: a phase 3 randomized, controlled trial in children and young infants at 11 African sites. (2014). PLoS Med, 11(7), e1001685. https://doi.org/10.1371/journal.pmed.1001685
3. Efficacy and safety of RTS,S/AS01 malaria vaccine with or without a booster dose in infants and children in Africa: final results of a phase 3, individually randomised, controlled trial. (2015). Lancet, 386(9988), 31-45. (NOT OA) https://doi.org/10.1016/s0140-6736(15)60721-8
4. RTS,S/AS01 malaria vaccine cost effective in Africa. (2015). [Article]. PharmacoEconomics & Outcomes News, 741(1), 22-22. https://doi.org/10.1007/s40274-015-2614-8 (NOT OA)
5. Aaby, P., Rodrigues, A., Kofoed, P.-E., Stabell Benn, C., & Benn, C. S. (2015). RTS,S/AS01 malaria vaccine and child mortality [commentary]. Lancet, 386(10005), 1735-1736. ( NOT OA) https://doi.org/10.1016/S0140-6736(15)00693-5
6. Agnandji, S. T., Fernandes, J. F., Bache, E. B., & Ramharter, M. (2015). Clinical development of RTS,S/AS malaria vaccine: a systematic review of clinical Phase I-III trials. Future Microbiology, 10(10), 1553-1578. https://doi.org/10.2217/fmb.15.90
7. Agnandji, S. T., Lell, B., Fernandes, J. F., Abossolo, B. P., Methogo, B. G., Kabwende, A. L., Adegnika, A. A., Mordmüller, B., Issifou, S., Kremsner, P. G., Sacarlal, J., Aide, P., Lanaspa, M., Aponte, J. J., Machevo, S., Acacio, S., Bulo, H., Sigauque, B., Macete, E., . . . Vansadia, P. (2012). A phase 3 trial of RTS,S/AS01 malaria vaccine in African infants. N Engl J Med, 367(24), 2284-2295. https://doi.org/10.1056/NEJMoa1208394 (NOT OA)
8. Agnandji, S. T., Lell, B., Soulanoudjingar, S. S., Fernandes, J. F., Abossolo, B. P., Conzelmann, C., Methogo, B. G., Doucka, Y., Flamen, A., Mordmüller, B., Issifou, S., Kremsner, P. G., Sacarlal, J., Aide, P., Lanaspa, M., Aponte, J. J., Nhamuave, A., Quelhas, D., Bassat, Q., . . . Vansadia, P. (2011). First results of phase 3 trial of RTS,S/AS01 malaria vaccine in African children. N Engl J Med, 365(20), 1863-1875. https://doi.org/10.1056/NEJMoa1102287 (NOT OA)
9. Arora, N., L, C. A., & Pannu, A. K. (2021). Towards Eradication of Malaria: Is the WHO's RTS,S/AS01 Vaccination Effective Enough? Risk Manag Health Policy, 14, 1033-1039. https://doi.org/10.2147/rmhp.S219294
10. Asante, K. P., Abdulla, S., Agnandji, S., Lyimo, J., Vekemans, J., Soulanoudjingar, S., Owusu, R., Shomari, M., Leach, A., Jongert, E., Salim, N., Fernandes, J. F., Dosoo, D., Chikawe, M., Issifou, S., Osei-Kwakye, K., Lievens, M., Paricek, M., Moller, T., . . . Lell, B. (2011). Safety and efficacy of the RTS,S/AS01(E) candidate malaria vaccine given with expanded-programme-on-immunisation vaccines: 19 month follow-up of a randomised, open-label, phase 2 trial. Lancet Infectious Diseases, 11(10), 741-749. https://doi.org/10.1016/s1473-3099(11)70100-1 (NOT OA)
11. Ballou, W. R. (2009). The development of the RTS,S malaria vaccine candidate: challenges and lessons. Parasite Immunology, 31(9), 492-500. https://doi.org/10.1111/j.1365-3024.2009.01143.x
12. BejonPhilip, White, M. T., Olotu, A., Bojang, K., Lusingu, J. P. A., Salim, N., Otsyula, N. N., Agnandji, S. T., Asante, K. P., Owusu-Agyei, S., Abdulla, S., & Ghani, A. C. (2013). Efficacy of RTS,S malaria vaccines: individual-participant pooled analysis of phase 2 data. The Lancet Infectious Diseases, 13(4), 319-327. (NOT OA)
13. Bell, G. J., Agnandji, S. T., Asante, K. P., Ghansah, A., Kamthunzi, P., Emch, M., & Bailey, J. A. (2021). Impacts of Ecology, Parasite Antigenic Variation, and Human Genetics on RTS,S/AS01e Malaria Vaccine Efficacy. Current Epidemiology Reports, 8(3), 79-88. https://doi.org/10.1007/s40471-021-00271-8 (NOT OA)
14. Bell, G. J., Goel, V., Essone, P., Dosoo, D., Adu, B., Mensah, B. A., Gyaase, S., Wiru, K., Mougeni, F., Osei, M., Minsoko, P., Sinai, C., Niaré, K., Juliano, J. J., Hudgens, M., Ghansah, A., Kamthunzi, P., Mvalo, T., Agnandji, S. T., & Bailey, J. A. (2022). Malaria Transmission Intensity Likely Modifies RTS, S/AS01 Efficacy Due to a Rebound Effect in Ghana, Malawi, and Gabon [journal article]. Journal of Infectious Diseases, 226(9), 1646-1656. https://doi.org/10.1093/infdis/jiac322 (NOT OA)
15. Bell, G. J., Loop, M., Topazian, H. M., Hudgens, M., Mvalo, T., Juliano, J. J., Kamthunzi, P., Tegha, G., Mofolo, I., Hoffman, I., Bailey, J. A., & Emch, M. (2020). Case reduction and cost-effectiveness of the RTS,S/AS01 malaria vaccine alongside bed nets in Lilongwe, Malawi. Vaccine, 38(25), 4079-4087. https://doi.org/10.1016/j.vaccine.2020.04.031 (NOT OA)
16. Bell, G. J., Loop, M. S., Mvalo, T., Juliano, J. J., Mofolo, I., Kamthunzi, P., Tegha, G., Lievens, M., Bailey, J., Emch, M., & Hoffman, I. (2020). Environmental modifiers of RTS,S/AS01 malaria vaccine efficacy in Lilongwe, Malawi. BMC public health, 20(1), 910. https://doi.org/10.1186/s12889-020-09039-z
17. Chandramohan, D., Zongo, I., Sagara, I., Cairns, M., Yerbanga, R. S., Diarra, M., Nikiema, F., Tapily, A., Sompougdou, F., Issiaka, D., Zoungrana, C., Sanogo, K., Haro, A., Kaya, M., Sienou, A. A., Traore, S., Mahamar, A., Thera, I., Diarra, K., . . . Greenwood, B. (2021). Seasonal Malaria Vaccination with or without Seasonal Malaria Chemoprevention. New England Journal of Medicine, 385(11), 1005-1017. https://doi.org/10.1056/NEJMoa2026330 (NOT OA)
18. Galactionova Katya, Tediosi, F., Camponovo, F., Smith, T. A., Gething, P. W., & Penny, M. A. (2017). Country specific predictions of the cost-effectiveness of malaria vaccine RTS,S/AS01 in endemic Africa. Vaccine, 35(1), 53-60.https://malariajournal.biomedcentral.com/articles/10.1186/s12936-017-1841-9
19. Grant, J., Sagara, I., Zongo, I., Cairns, M., Yerbanga, R. S., Diarra, M., Zoungrana, C., Issiaka, D., Nikièma, F., Sompougdou, F., Tapily, A., Kaya, M., Haro, A., Sanogo, K., Sienou, A. A., Traore, S., Thera, I., Yalcouye, H., Kuepfer, I., . . . Ouédraogo, J. B. (2022). Impact of seasonal RTS,S/AS01(E) vaccination plus seasonal malaria chemoprevention on the nutritional status of children in Burkina Faso and Mali. Malar J, 21(1), 59. https://doi.org/10.1186/s12936-022-04077-x
20. Greenwood, B., Cairns, M., Chaponda, M., Chico, R. M., Dicko, A., Ouedraogo, J. B., Phiri, K. S., Ter Kuile, F. O., & Chandramohan, D. (2021). Combining malaria vaccination with chemoprevention: a promising new approach to malaria control. Malar J, 20(1), 361. https://doi.org/10.1186/s12936-021-03888-8
21. Greenwood Brian, Dicko, A., Sagara, I., Zongo, I., Tinto, H., Cairns, M., Kuepfer, I., Milligan, P., Ouedraogo, J.-B., Doumbo, O., & Chandramohan, D. (2017). Seasonal vaccination against malaria: a potential use for an imperfect malaria vaccine. Malaria Journal, 16(1), 182-182.
https://malariajournal.biomedcentral.com/articles/10.1186/s12936-017-1841-9
22. Guerra Mendoza, Y., Garric, E., Leach, A., Lievens, M., Ofori-Anyinam, O., Pirçon, J. Y., Stegmann, J. U., Vandoolaeghe, P., Otieno, L., Otieno, W., Owusu-Agyei, S., Sacarlal, J., Masoud, N. S., Sorgho, H., Tanner, M., Tinto, H., Valea, I., Mtoro, A. T., Njuguna, P., . . . Schuerman, L. (2019). Safety profile of the RTS,S/AS01 malaria vaccine in infants and children: additional data from a phase III randomized controlled trial in sub-Saharan Africa. Hum Vaccin Immunother, 15(10), 2386-2398. https://doi.org/10.1080/21645515.2019.1586040
23. Gyaase, S., Asante, K. P., Adeniji, E., Boahen, O., Cairns, M., & Owusu-Agyei, S. (2021). Potential effect modification of RTS,S/AS01 malaria vaccine efficacy by household socio-economic status. BMC public health, 21(1), 240. https://doi.org/10.1186/s12889-021-10294-x
24. Han, L., Hudgens, M. G., Emch, M. E., Juliano, J. J., Keeler, C., Martinson, F., Kamthunzi, P., Tegha, G., Lievens, M., & Hoffman, I. F. (2017). RTS, S/AS01 Malaria Vaccine Efficacy is Not Modified by Seasonal Precipitation: Results from a Phase 3 Randomized Controlled Trial in Malawi. Scientific Reports, 7, Article 7200. https://doi.org/10.1038/s41598-017-07533-w
25. Hogan, A. B., Winskill, P., & Ghani, A. C. (2020). Estimated impact of RTS,S/AS01 malaria vaccine allocation strategies in sub-Saharan Africa: A modelling study. PLoS Med, 17(11), e1003377. https://doi.org/10.1371/journal.pmed.1003377
26. Ndeketa, L., Mategula, D., Terlouw, D. J., Bar-Zeev, N., Sauboin, C. J., & Biernaux, S. (2020). Cost-effectiveness and public health impact of RTS,S/AS01 (E) malaria vaccine in Malawi, using a Markov static model. Wellcome Open Res, 5, 260. https://doi.org/10.12688/wellcomeopenres.16224.2
27. Penny, M. A., Galactionova, K., Tarantino, M., Tanner, M., & Smith, T. A. (2015). The public health impact of malaria vaccine RTS,S in malaria endemic Africa: country-specific predictions using 18 month follow-up Phase III data and simulation models. BMC Med, 13, 170. https://doi.org/10.1186/s12916-015-0408-2
28. Penny Melissa, A., Verity, R., Bever, C. A., Sauboin, C., Galactionova, K., Flasche, S., White, M. T., Wenger, E. A., Van de Velde, N., Pemberton-Ross, P., Griffin, J. T., Smith, T. A., Eckhoff, P. A., Muhib, F., Jit, M., & Ghani, A. C. (2016). Public health impact and cost-effectiveness of the RTS,S/AS01 malaria vaccine: a systematic comparison of predictions from four mathematical models. Lancet, 387(10016), 367-375. (NOT OA)
29 Rosenthal, P. J. (2015). The RTS,S/AS01 vaccine continues to show modest protection against malaria in African infants and children [Article]. Evidence Based Medicine, 20(5), 179-179. https://doi.org/10.1136/ebmed-2015-110231
30. Samuels, A. M., Ansong, D., Kariuki, S. K., Adjei, S., Bollaerts, A., Ockenhouse, C., Westercamp, N., Lee, C. K., Schuerman, L., Bii, D. K., Osei-Tutu, L., Oneko, M., Lievens, M., Attobrah Sarfo, M. A., Atieno, C., Morelle, D., Bakari, A., Sang, T., Jongert, E., . . . Agbenyega, T. (2022). Efficacy of RTS,S/AS01(E) malaria vaccine administered according to different full, fractional, and delayed third or early fourth dose regimens in children aged 5-17 months in Ghana and Kenya: an open-label, phase 2b, randomised controlled trial. Lancet Infect Dis, 22(9), 1329-1342. https://doi.org/10.1016/s1473-3099(22)00273-0 (NOT OA)
31. Sicuri, E., Yaya Bocoum, F., Nonvignon, J., Alonso, S., Fakih, B., Bonsu, G., Kariuki, S., Leeuwenkamp, O., Munguambe, K., Mrisho, M., Were, V., & Sauboin, C. (2019). The Costs of Implementing Vaccination With the RTS,S Malaria Vaccine in Five Sub-Saharan African Countries. MDM Policy Pract, 4(2), 2381468319896280. https://doi.org/10.1177/2381468319896280
32. Thompson, H. A., Hogan, A. B., Walker, P. G. T., Winskill, P., Zongo, I., Sagara, I., Tinto, H., Ouedraogo, J. B., Dicko, A., Chandramohan, D., Greenwood, B., Cairns, M., & Ghani, A. C. (2022). Seasonal use case for the RTS,S/AS01 malaria vaccine: a mathematical modelling study. Lancet Glob Health, 10(12), e1782-e1792. https://doi.org/10.1016/s2214-109x(22)00416-8 (NOT OA)
33. Tinto, H., D'Alessandro, U., Sorgho, H., Valea, I., Tahita, M. C., Kabore, W., Kiemde, F., Lompo, P., Ouedraogo, S., Derra, K., Ouedraogo, F., Ouedraogo, J. B., Ballou, W. R., Cohen, J., Guerra, Y., Heerwegh, D., Jongert, E., Lapierre, D., Leach, A., . . . Partnership, R. S. C. T. (2015). Efficacy and safety of RTS,S/AS01 malaria vaccine with or without a booster dose in infants and children in Africa: final results of a phase 3, individually randomised, controlled trial. Lancet, 386(9988), 31-45. (NOT OA) https://doi.org/10.1016/s0140-6736(15)60721-8
34. Tinto Halidou, Otieno, W., Gesase, S., Sorgho, H., Otieno, L., Liheluka, E., Valéa, I., Sing'oei, V., Malabeja, A., Valia, D., Wangwe, A., Gvozdenovic, E., Guerra Mendoza, Y., Jongert, E., Lievens, M., Roman, F., Schuerman, L., & Lusingu, J. (2019). Long-term incidence of severe malaria following RTS,S/AS01 vaccination in children and infants in Africa: an open-label 3-year extension study of a phase 3 randomised controlled trial. The Lancet Infectious Diseases, 19(8), 821-832. (NOT OA)
35. White, M. T., Griffin, J. T., Drakeley, C. J., & Ghani, A. C. (2010). Heterogeneity in malaria exposure and vaccine response: implications for the interpretation of vaccine efficacy trials. Malaria Journal, 9, Article 82. https://doi.org/10.1186/1475-2875-9-82
Duffy, P.E. and Patrick Gorres, J., 2020. Malaria vaccines since 2000: progress, priorities, products. npj Vaccines, 5(1), p.48. https://www.nature.com/articles/s41541-020-0196-3
Beeson, J.G., Kurtovic, L., Valim, C., Asante, K.P., Boyle, M.J., Mathanga, D., Dobano, C. and Moncunill, G., 2022. The RTS, S malaria vaccine: Current impact and foundation for the future. Science translational medicine, 14(671), p.eabo6646. (NOT OA)
Duffy, P.E., 2022. Making a good malaria vaccine better. Trends in Parasitology, 38(1), pp.9-10. (NOT OA)
Mendoza, Y.G., Garric, E., Leach, A., Lievens, M., Ofori-Anyinam, O., Pirçon, J.Y., Stegmann, J.U., Vandoolaeghe, P., Otieno, L., Otieno, W. and Owusu-Agyei, S., 2019. Safety profile of the RTS, S/AS01 malaria vaccine in infants and children: additional data from a phase III randomized controlled trial in sub-Saharan Africa. Human vaccines & immunotherapeutics. https://doi.org/10.1080/21645515.2019.1586040